<DOC>
	<DOC>NCT01652313</DOC>
	<brief_summary>The purpose of this study is to fulfil regulatory requirements for registration of a new chemical entity in China. Rasagiline is approved for the treatment of Parkinson's Disease (PD) in Europe and the US. Rasagiline is safe and well tolerated in healthy subjects, and the efficacy and safety has been demonstrated in placebo- and active comparator-controlled phase III studies.</brief_summary>
	<brief_title>Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>The subject is a Chinese man or woman The subject is, in the opinion of the investigator, generally healthy If female, the subject must have a negative pregnancy test at screening and baseline, and agree not to try to become pregnant from Screening until after the Followup Visit The subject is, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason. Other inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>